Cite
HARVARD Citation
Akamatsu, H. et al. (2020). Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer. Oncologist. pp. e679-e683. [Online].